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Metastatic carcinoid tumour of the heart
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A 68-year-old woman presenting with metastatic carcinoid tumours of the liver and pan-
creas was referred for CMR imaging because of LV location on somatostatin receptor
scintigraphy imaging, a speciﬁc test for carcinoid neuroendocrine tumours (Fig. 1, Panel
A). She did not have any clinical carcinoid symptoms and her urinary 5-hydroxyindole acetic
acid concentration was raised.
Echocardiography showed: a 17× 31mm, well circumscribed, homogeneous, non-
inﬁltrating tumour, located in the lateral LV wall (Fig. 1, Panel B); left-sided valvular
involvement with moderate thickening and insufﬁciency of the mitral valve (Fig. 1, Panel
B, arrow A); and an aneurysmal interatrial septum (Fig. 1, Panel B, arrow B; Video 1). Con-
trast echocardiography revealed substantial right-to-left shunting of microbubbles across
the atrial septum at rest, consistent with a PFO. The rest of this test was normal without
any right-sided valvular dysfunction.
CMR imaging showed a 20× 20× 29mm, homogeneous, circumscribed mass developed
in the lateral LV wall, extending into the pericardium without effusion (Videos 2 and 3).
On black blood T1-weighted images, this mass had a slightly higher signal than the adja-
cent myocardium (Fig. 1, Panel C), without any decrease in signal intensity using a fat
presaturation technique. After ﬁrst-pass intravenous gadolinium, there was early tumour
enhancement (Video 4). T1-weighted inversion recovery gradient echo images showed
heterogeneous enhancement of this mass (Fig. 1, Panel D).Scintigraphie des
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Foramen oval
perméable
Somatostatin analogue treatment (lanreotide) was started. After 6-month follow-up,
this patient was still free of clinical cardiac symptoms and the most recent CMR image did
not show any progression of the mass.
Therapeutic options are pharmacological (with somatostatin analogue treatment to
control vasoactive substance release), surgical (cases of severe valvular dysfunction) in
Abbreviations: CMR, cardiac magnetic resonance; LV, left ventricular; PFO, patent foramen ovale.
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Appendix A. Supplementary dataigure 1. Panel A: Somatostatin receptor scintigraphy imaging.
1-weighted echo images before gadolinium injection. Panel D: T1-
nd possibly interventional (with percutaneous closure of
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2l B: Cardiac echocardiography, 4-chamber. Panel C: Black blood
hted inversion recovery gradient echo images.upplementary data associated with this article can
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